XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.1

License Agreements - Merus (Details) $ in Thousands	1 Months Ended			3 Months Ended
	Jan. 31, 2023 USD ($)	Jan. 31, 2022 item	Dec. 31, 2016 item	Mar. 31, 2023 USD ($) shares	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)
License Agreements
Unrealized gain (loss) on long term investments				$ (5,318)	$ (46,585)
Merus
License Agreements
Common stock held from investment (in shares) | shares				3,600,000
Fair market value of our long term investments				$ 65,300		$ 54,900
Unrealized gain (loss) on long term investments				10,400	$ (19,000)
Merus
License Agreements
Number of independent programs | item			10
Number of additional preclinical discovery programs | item		10
Number of programs under the resulting products are co-funded for development | item		2
Associated future global development costs , if elected to co-develop (as a percent)		35.00%
Milestone payment made under license agreement	$ 2,500			$ 5,500
Merus | UNITED STATES
License Agreements
Profit sharing (as a percent)				50.00%
Percentage of profit (losses)				50.00%
Merus | Minimum
License Agreements
Royalty payments on future global net sales (as a percent)				6.00%
Merus | Minimum | Non-US
License Agreements
Royalty payments on future global net sales (as a percent)				6.00%
Merus | Maximum
License Agreements
Royalty payments on future global net sales (as a percent)				10.00%
Merus | Maximum | UNITED STATES
License Agreements
Royalty payments on future global net sales (as a percent)				4.00%
Merus | Maximum | Non-US
License Agreements
Royalty payments on future global net sales (as a percent)				10.00%
Merus | Development and Regulatory Milestones | Maximum
License Agreements
Additional milestone payments under the license agreement				$ 100,000
Merus | Commercialization Milestones | Maximum
License Agreements
Additional milestone payments under the license agreement				$ 250,000

X

- Definition

Represents the percentage of profits and losses shared under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	incy_CollaborationAgreementProfitSharingPercentage
Namespace Prefix:	incy_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the additional milestone payments to be made under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementAdditionalMilestonePayments
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Represents the maximum number of independent programs encompassed under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementMaximumNumberOfIndependentPrograms
Namespace Prefix:	incy_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the amount of the milestone payment made under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementMilestonePaymentAmountPaid
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the number of additional preclinical discovery programs.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementNumberOfAdditionalPreclinicalDiscoveryPrograms
Namespace Prefix:	incy_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the number of programs in which the resulting products are co-funded for development.

+ References

No definition available.

+ Details

Name:	incy_NumberOfProgramsUnderWhichResultingProductsAreCoFundedForDevelopment
Namespace Prefix:	incy_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the percentage of associated future global development costs from the initiation of a Phase IIb trial provided the entity elects to co-develop any compounds and/or indications.

+ References

No definition available.

+ Details

Name:	incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds
Namespace Prefix:	incy_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the percentage of profits (losses).

+ References

No definition available.

+ Details

Name:	incy_PercentageOfProfitsLosses
Namespace Prefix:	incy_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized.

+ References

No definition available.

+ Details

Name:	incy_PercentageOfRoyaltyRatePayments
Namespace Prefix:	incy_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(3)(d))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 321
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714

+ Details

Name:	us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Balance held at close of period in number of shares.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 50
-Paragraph 6
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column B))
-URI https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010

+ Details

Name:	us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258

+ Details

Name:	us-gaap_InvestmentsFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=incy_MerusNVMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=incy_MerusNVMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: